drugset / Trial / NCT07487467

Autologous SVF Therapy for Type 2 Diabetes

NCT07487467

Recruiting 10 enrolled Kaiser Clinic and Hospital
NaSingle-groupOpen-labelTreatment

Summary

This prospective clinical study aims to evaluate the safety and efficacy of autologous adipose-derived stromal vascular fraction (SVF), enriched with mesenchymal stem cells (ADSCs), for the treatment of Type 2 Diabetes Mellitus (T2DM). Adipose tissue will be harvested using a 1210-nm diode laser-assisted selective photochemical stimulation technique (One-STEP™ method), followed by centrifugation without enzymatic digestion. The isolated SVF will be injected endoluminally into the duodenal submucosa during the same surgical procedure. Five adult patients with T2DM will be followed for six months to assess metabolic control, pancreatic function, and quality of life outcomes.

Timeline

Start
2025-01-20
Primary completion
2026-03-16
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject AUTOLOGOUS ADIPOSE-DERIVED STROMAL VASCULAR FRACTION Cell therapy Other